Gotham Asset Management LLC Purchases New Holdings in Keryx Biopharmaceuticals, Inc. (KERX)
Gotham Asset Management LLC purchased a new stake in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 55,639 shares of the biopharmaceutical company’s stock, valued at approximately $402,000.
A number of other large investors have also recently made changes to their positions in KERX. State Street Corp boosted its holdings in Keryx Biopharmaceuticals by 20.1% in the 1st quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock valued at $21,432,000 after purchasing an additional 582,624 shares during the period. Monarch Partners Asset Management LLC bought a new stake in shares of Keryx Biopharmaceuticals during the 2nd quarter worth $3,059,000. Chicago Equity Partners LLC bought a new stake in shares of Keryx Biopharmaceuticals during the 2nd quarter worth $2,756,000. Vanguard Group Inc. lifted its holdings in shares of Keryx Biopharmaceuticals by 5.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after acquiring an additional 349,521 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in shares of Keryx Biopharmaceuticals by 24.3% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after acquiring an additional 326,285 shares during the last quarter. 65.19% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on KERX shares. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Maxim Group set a $9.00 price objective on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Finally, Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and a consensus target price of $7.48.
Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at 6.50 on Friday. Keryx Biopharmaceuticals, Inc. has a 1-year low of $4.11 and a 1-year high of $8.38. The firm has a 50-day moving average of $7.17 and a 200 day moving average of $6.77. The company’s market capitalization is $771.88 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The business had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.51 million. During the same quarter last year, the business earned ($0.42) EPS. Keryx Biopharmaceuticals’s revenue for the quarter was up 62.4% compared to the same quarter last year. On average, analysts anticipate that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current year.
Keryx Biopharmaceuticals Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.